Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial-Reference-Cited by-同舟云学术

Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial

Published:2023-01-18 Issue:1 Volume:8 Page:146-153
ISSN:2470-9239
Container-title:Epilepsia Open
language:en
Short-container-title:Epilepsia Open

Author:

Farkas Mark Kristof¹^ORCID,Beller Cynthia²,Bozorg Ali²,McClung Carrie²,Roebling Robert³,Yates Tanisia²,Yuen Nancy²,Makedonska Iryna⁴

Affiliation:

1. First Department of Pediatrics Semmelweis University Budapest Hungary

2. UCB Pharma Morrisville North Carolina USA

3. UCB Pharma Monheim am Rhein Germany

4. Dnipro City Pediatric Clinical Hospital Dnipro Ukraine

Funder

UCB Pharma

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/epi4.12682

Reference16 articles.

1. Current understanding of the mechanism of action of the antiepileptic drug lacosamide

2. UCB Pharma.Vimpat® (lacosamide tablets injection oral solution) [US Prescribing Information]. Available at:https://www.ucb.com/_up/ucb_com_products/documents/Vimpat_Labeling_Oct_2021.pdf. Accessed November 3 2021.

3. UCB Pharma.Vimpat® (lacosamide) EMA Summary of Product Characteristics. Available at:https://www.ema.europa.eu/en/documents/product‐information/vimpat‐epar‐product‐information_en.pdf. Accessed November 3 2021.

4. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures

5. National Library of Medicine (U.S).Efficacy and safety of lacosamide as adjunctive therapy in subjects ≥1 month to <4 years with partial‐onset seizures. Identifier: NCT02477839. Available at:https://clinicaltrials.gov/ct2/show/study/NCT02477839

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy;Epilepsy & Behavior;2024-10

2. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior;Epilepsy & Behavior;2023-09